Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety

LGM Pharma commits $15M to US facilities in major CDMO expansion

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing

$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs

The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention

Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment

Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy

NATCO launches Semaglutide generic injection multi dose vials in India at affordable price of Rs. 1,290

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma